Showing 4931-4940 of 5910 results for "".
- Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trialhttps://modernod.com/news/last-patient-last-visit-completed-in-regenerx-phase-3-dry-eye-clinical-trial/2478508/RegeneRx Biopharmaceuticals announced that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up. ARISE-3 is designed to assess the safety and efficacy of 0.1% RGN-259 eye drops compared to placebo after 2 weeks of
- Oxurion NV Confirms New Patents for THR-687 Issued by European and US Patent Officeshttps://modernod.com/news/oxurion-nv-confirms-new-patents-for-thr-687-issued-by-european-and-us-patent-offices/2478504/Oxurion NV announced a strengthening of its intellectual property (IP) portfolio governing THR-687, an integrin antagonist being developed for the treatment of DME. The European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) have both issued new composition-o
- COVID-19 Vaccine Safety Efforts to Feature App Tracking of Vulnerable Groupshttps://modernod.com/news/covid-19-vaccine-safety-efforts-to-feature-app-tracking-of-vulnerable-groups/2478501/Government health officials and drugmakers plan to roll out extra tools to detect whether COVID-19 vaccines cause any serious side effects once the shots are cleared for widespread use, aiming to fill gaps in existing safeguards given the expected speed and scope of
- First COVID-19 Vaccine Doses To Go To Health Workers, Say CDC Advisershttps://modernod.com/news/first-covid-19-vaccine-doses-to-go-to-health-workers-say-cdc-advisers/2478502/Health care workers will almost certainly get the first doses of COVID-19 vaccine in the U.S. when one is approved, according to Dr. José Romero, head of the committee that develops evidence-based immunization guidelines for the Centers for Disease Control and Prevention, as
- How Best to Combat Post-Keratoplasty Infections Isn’t Always Clearhttps://modernod.com/news/how-best-to-combat-post-keratoplasty-infections-isnt-always-clear/2478503/Infection is one of the most dreaded complications after ocular surgery. Although it is considered rare, the rate of fungal infections after corneal transplantation is nonetheless increasing in the United States. As detailed in a recent r
- Pfizer Goes Solo on U.S. Shot Distribution, Opting Out of Government Channelshttps://modernod.com/news/pfizer-goes-solo-on-u-s-shot-distribution-opting-out-of-government-channels/2478499/Pfizer had already made it quite clear that it doesn’t need the U.S. government to help distribute its COVID-19 vaccine, should it be authorized by the FDA. Now it’s putting an exclamation point on that declaration, according to a FiercePharma
- Clots, Strokes And Rashes. Is COVID-19 A Disease Of The Blood Vessels?https://modernod.com/news/clots-strokes-and-rashes-is-covid-19-a-disease-of-the-blood-vessels/2478497/Whether it’s strange rashes on the toes or blood clots in the brain, the widespread ravages of COVID-19 have increasingly led researchers to focus on how the novel coronavirus sabotages the body’s blood vessels, according to an NPR
- Technique to Regenerate Optic Nerve Offers Hope for Future Glaucoma Treatmenthttps://modernod.com/news/technique-to-regenerate-optic-nerve-offers-hope-for-future-glaucoma-treatment/2478496/Scientists have used gene therapy to regenerate damaged nerve fibres in the eye, in a discovery that could aid the development of new treatments for glaucoma, according to a Medical Xpress report. </
- What a Republican Senate Will Mean for the Health Care Industryhttps://modernod.com/news/what-a-republican-senate-will-mean-for-the-health-care-industry/2478493/Republicans appear likely to hold on slightly to their Senate majority after Tuesday’s elections, which could have a major impact on what healthcare legislation gets through Congress next year, according to a FierceHealthcare
- Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for Lytenava for Retinal Diseaseshttps://modernod.com/news/outlook-therapeutics-completes-patient-enrollment-of-open-label-safety-study-for-lytenava-for-retinal-diseases/2478490/Outlook Therapeutics announced the completion of patient enrollment for its planned open-label safety study evaluating ONS-5010/Lytenava (NORSE THREE). Patient enrollment for the study was completed in less than 1 month, ahead of the planned 4-month enrollment schedule.